Authors: Prof. Guido Barbagli, Dr. med. Gouya Ram-Liebig Native oral mucosa is implanted since many years as graft for urethroplasty. However, its excision from the mouth may be associated with potential complications and morbidities at oral site. Early complications include pain, numbness, bleeding, and infection while longer-term complications comprise oral tightness and restriction of…
The ready availability of tissues and organs to replace and repair those that have been damaged is an important clinical need. The field of tissue engineering might offer an innovative solution.
In Europe TEPs, somatic cell therapy medicinal products, and gene therapy medicinal products are summarised under the term advanced therapy medicinal products (ATMP) [1,2]. TEPs contain viable autolo- gous, allogenic or xenogenic cells.
The following publication shows the development of the first urology tissue engineering product starting from preclinic to market approval in Germany:
Abstract MP9-04: Preclinical and clinical examination of tissue-engineered graft for urethral reconstruction (MukoCell®) with regard to its safety
The quality and pre-clinical data of our lead product MukoCell have been certified by the European Medicines Agency (EMA).
UroTiss GmbH is particapting at 66th German Congress of Urology which will take place from October 1 to October 4, 2014, in Düsseldorf on the Rhine.
UroTiss GmbH is particapting at the 29. Annual EAU Congress from April 11th – 15th 2014
UroTiss GmbH has received authorisation to distribute its product MukoCell® pursuant to Section 4b of the Medicinal Products Act (AMG) – „Special provisions governing advanced therapy medicinal products“.
In the article „Business creation in Germany / A slow climb – A vigorous start-up scene has yet to produce its first big breakthrough“ published in The Economist from 5th October 2013, the UroTiss GmbH gets mentioned as one of Germanys promising Start-up companies in the field of Bioengineering.